Pimitespib purchase price and import route and cost comparison in Japan

Pimetibib is a new type of HSP90 inhibitor that has not yet been officially launched in China, so patients cannot purchase it through domestic hospitals or pharmacies. The drug is currently only available in Japan, developed by the Japanese pharmaceutical company Taiho and sold under the trade name "Jeselhy". It is mainly used to treat patients with gastrointestinal stromal tumors (GIST) who have failed previous treatments. Because it is an innovative original drug in Japan and has a relatively high price, equivalent to about more than 10,000 yuan in RMB, there are currently no generic drugs of pimitebi available on the market.

If domestic patients need to obtain pimetibib, the main way is to introduce it through regular overseas pharmacies or cross-border medical services. One way is to go to Japan for medical treatment, issue a prescription at a local Japanese hospital and purchase it at a pharmacy; the other way is to use a qualified cross-border drug direct mail platform to mail the medicine back to China from a Japanese pharmacy. In addition, hospitals in some areas may also apply for drug introduction through special imported drug channels, but the overall process is relatively complex and requires high information and qualifications.

The price of the original Japanese drug of Pimitebi is inherently high. In addition to the costs of transportation, customs clearance, agency services, etc., the final price of the drug for patients is often higher than the basic drug price of more than 10,000 yuan. If you go to Japan for medical treatment and purchase medicine by yourself, in addition to the medicine fee, you also need to pay for air tickets, accommodation, translation and medical treatment. Choosing cross-border mail order saves travel costs, but you need to pay additional service fees and transportation insurance fees. Therefore, the total cost under different import methods varies greatly and needs to be comprehensively considered based on the actual situation of the patient.

There are certain risks associated with purchasing pimetibib through overseas channels, such as drug quality assurance during transportation, risks of customs seizure, and the possibility of counterfeit or inferior drugs through informal channels. It is recommended that patients must go through formal medical institutions or qualified cross-border drug purchase platforms and use drugs under the guidance of professional doctors. As the speed of domestic drug review and approval accelerates, pimetibi is expected to be launched in China in the future, and the accessibility and cost of purchasing drugs will be greatly improved by then.

Reference link:https://www.drugs.com